September 29, 2022 08:19 ET | Source: Biomerica, Inc.
...
Aware® is a simple at-home device to increase sensitivity in breast self-exams. About 80% of breast cancer is detected by women themselves who notice changes in their breast.
EZ Detect™ is a simple 2-minute, at-home test which detects an early warning sign of colorectal cancer
IRVINE, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that the Company’s Aware® Breast Self Exam device and EZ Detect Colon Disease test are now being sold on Amazon and fulfilled by Amazon.
Aware: https://www.amazon.com/gp/product/B010OVMR2S/ref=ewc_pr_img_1?smid=A12JU5SP5PIFD3&psc=1
EZ Detect: https://www.amazon.com/gp/product/B00EF2BPZ8/ref=ewc_pr_img_1?smid=A12JU5SP5PIFD3&psc=1
The Biomerica FDA-cleared Aware® Breast Self Exam device is a revolutionary way for women to enhance tactile sensitivity to changes or irregularities in breast tissue, making breast self-exams easy and convenient. The Aware® device can facilitate an effective self-exam and can serve as a reminder to perform a breast self-exam every month.
Breast Cancer is the most common cancer among women. Unfortunately, every woman is potentially at risk, as more than 70% of women diagnosed have no family history of breast cancer. Early detection significantly improves the chances that breast cancer can be diagnosed and treated successfully. Survival rates are as high as 99% when the cancer is found early while still localized in the breast. However, if the cancer has spread to the regional lymph nodes, the 5-year survival rate falls to 86%[1,2]. About 80% of breast cancer cases are detected because women themselves notice changes in their breast[3]. This highlights the important role that each woman can play in managing their own health. However, a breast self-examination is not a replacement for regular medical visits and periodic ultrasound or mammography. All three steps are important to finding breast cancer early. The relevance of early detection cannot be overemphasized.
The Biomerica EZ Detect™ Colon Disease Test is the simplest in-home, two-minute diagnostic test to detect hidden blood in the stool, one of the primary early warning signs of colorectal disease. The test does not require handling of stool or dietary restrictions.
Colorectal cancer (“CRC”) is the second most common cause of cancer death in the United States. In 2020, an estimated 147,950 individuals would be diagnosed with CRC and an estimated 53,200 would die from the disease, including 17,930 cases and 3,640 deaths in individuals under the age of 50[4].
In a study performed by Johns Hopkins University, EZ Detect™ was preferred 10:1 by patients over another fecal occult blood test. Published studies have also indicated that the best colorectal screening test is “the one that gets done.”[5] With EZ Detect, the user simply drops a test pad onto the surface of the water in the toilet bowl after a bowel movement. If blood is present in the person’s stool, a blue-green indicator will appear on the test pad within two minutes. The pad is then simply flushed down the toilet. Other colorectal screening tests require collecting a stool sample and mailing it to a lab for processing. Requiring a patient to collect and mail a stool sample results in a high percentage of these competing tests never being performed by patients[6]. EZ Detect is simple to perform and provides results in just two minutes.
Zack Irani, Chief Executive Officer of Biomerica, commented, “The key to better outcomes in all cancers is early detection and regular screening. Both Aware and EZ Detect are inexpensive and easy to use. Both can be performed in the privacy of one’s home. I’m proud of the work we do to produce products that help save lives and improve the health of people.”
For further information about the Aware® Breast Self Exam Product and the EZ Detect Colon Disease test, please visit https://AwareBSE.com and https://ezdetect.com
About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company’s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica’s primarily focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
1. https://www.webmd.com/breast-cancer/guide/breast-cancer-survival-rates. Accessed 08 July 2022
2. https://www.cancer.net/cancer-types/breast-cancer/statistics. Accessed 08 July 2022
3. https://www.pinkribbon-deutschland.de/vorsorge-fakten/fakten, accessed 02 AUG 2022
4. Siegel, R.L., et al., Colorectal cancer statistics, 2020. CA Cancer J Clin, 2020. 70(3): p. 145-164.
5. Lansdorp-Vogelaar, I., A.B. Knudsen, and H. Brenner, Cost-effectiveness of colorectal cancer screening - an overview. Best Pract Res Clin Gastroenterol, 2010. 24(4): p. 439-49.
6. Navarro, M., et al., Colorectal cancer population screening programs worldwide in 2016: An update. World J Gastroenterol, 2017. 23(20): p. 3632-3642.
Recent BMRA News
- Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain • GlobeNewswire Inc. • 10/30/2024 12:19:00 PM
- Biomerica Reports First Quarter Fiscal 2025 Financial Results • GlobeNewswire Inc. • 10/16/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/15/2024 09:00:36 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/30/2024 09:00:08 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/20/2024 09:00:04 PM
- The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer • GlobeNewswire Inc. • 09/04/2024 12:19:00 PM
- Biomerica Reports Fiscal 2024 Year End Results • GlobeNewswire Inc. • 08/29/2024 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/28/2024 09:00:33 PM
- Biomerica Launches At-Home Sample Collection for inFoods® IBS, Significantly Expanding Access for Millions of IBS Sufferers • GlobeNewswire Inc. • 07/01/2024 11:47:00 AM
- Biomerica Announces inFoods® IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024 • GlobeNewswire Inc. • 05/13/2024 12:19:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/10/2024 09:20:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 09:15:25 PM
- Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement • GlobeNewswire Inc. • 04/29/2024 12:19:00 PM
- Biomerica provides update on inFoods® IBS expansion • GlobeNewswire Inc. • 04/15/2024 11:47:00 AM
- Biomerica Reports Third Quarter 2024 Financial Results • GlobeNewswire Inc. • 04/12/2024 11:23:53 PM
- Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference • GlobeNewswire Inc. • 03/28/2024 12:19:00 PM
- Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board • GlobeNewswire Inc. • 02/21/2024 01:19:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 02:00:06 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/09/2024 08:06:57 PM
- Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica • GlobeNewswire Inc. • 01/23/2024 01:19:00 PM
- Biomerica Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 01/16/2024 01:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 12:00:32 PM
- Biomerica Received US FDA 510(k) Clearance for Their Hp Detect™ ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects Approximately 35% of the U.S. Population • GlobeNewswire Inc. • 12/18/2023 12:47:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/14/2023 10:10:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/14/2023 10:10:31 PM
FEATURED Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • Oct 30, 2024 12:22 PM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM